Vamorolone

Active substance

Delta-1,4,9(11)-pregnatriene-17,21-dihydroxy-16-alpha-methyl-3,20-

dione

Holder

Santhera Pharmaceuticals (Switzerland)

Status

Running

Indication

Duchenne Muscular Dystrophy in boys who are completing the VBP15-004 trial

Public documents

Approbation

Approbation amendment_1

Approbation-Amendment_2

Information for the patient

Information for the patient - amendment_1

Information for the patient-Amendment_2

Informed consent

Informed consent - amendment_1

Informed consent-Amendment_2

Last update

23/052023

Last updated on 13/02/2024